QQQ   270.06 (+0.25%)
AAPL   438.70 (+0.68%)
MSFT   213.23 (-1.53%)
FB   252.25 (+0.12%)
GOOGL   1,480.48 (-0.15%)
AMZN   3,164.52 (+1.69%)
NVDA   443.96 (+0.81%)
CGC   19.38 (+1.68%)
BABA   259.43 (+0.58%)
TSLA   1,505.26 (+1.36%)
MU   51.29 (+1.79%)
GE   6.15 (+0.65%)
AMD   82.74 (+6.53%)
T   29.96 (+1.15%)
F   6.85 (+2.39%)
ACB   10.59 (+1.63%)
GILD   71.05 (-0.95%)
NFLX   505.87 (+1.45%)
DIS   116.71 (+0.31%)
BAC   24.92 (-0.28%)
BA   166.55 (+2.64%)
QQQ   270.06 (+0.25%)
AAPL   438.70 (+0.68%)
MSFT   213.23 (-1.53%)
FB   252.25 (+0.12%)
GOOGL   1,480.48 (-0.15%)
AMZN   3,164.52 (+1.69%)
NVDA   443.96 (+0.81%)
CGC   19.38 (+1.68%)
BABA   259.43 (+0.58%)
TSLA   1,505.26 (+1.36%)
MU   51.29 (+1.79%)
GE   6.15 (+0.65%)
AMD   82.74 (+6.53%)
T   29.96 (+1.15%)
F   6.85 (+2.39%)
ACB   10.59 (+1.63%)
GILD   71.05 (-0.95%)
NFLX   505.87 (+1.45%)
DIS   116.71 (+0.31%)
BAC   24.92 (-0.28%)
BA   166.55 (+2.64%)
QQQ   270.06 (+0.25%)
AAPL   438.70 (+0.68%)
MSFT   213.23 (-1.53%)
FB   252.25 (+0.12%)
GOOGL   1,480.48 (-0.15%)
AMZN   3,164.52 (+1.69%)
NVDA   443.96 (+0.81%)
CGC   19.38 (+1.68%)
BABA   259.43 (+0.58%)
TSLA   1,505.26 (+1.36%)
MU   51.29 (+1.79%)
GE   6.15 (+0.65%)
AMD   82.74 (+6.53%)
T   29.96 (+1.15%)
F   6.85 (+2.39%)
ACB   10.59 (+1.63%)
GILD   71.05 (-0.95%)
NFLX   505.87 (+1.45%)
DIS   116.71 (+0.31%)
BAC   24.92 (-0.28%)
BA   166.55 (+2.64%)
QQQ   270.06 (+0.25%)
AAPL   438.70 (+0.68%)
MSFT   213.23 (-1.53%)
FB   252.25 (+0.12%)
GOOGL   1,480.48 (-0.15%)
AMZN   3,164.52 (+1.69%)
NVDA   443.96 (+0.81%)
CGC   19.38 (+1.68%)
BABA   259.43 (+0.58%)
TSLA   1,505.26 (+1.36%)
MU   51.29 (+1.79%)
GE   6.15 (+0.65%)
AMD   82.74 (+6.53%)
T   29.96 (+1.15%)
F   6.85 (+2.39%)
ACB   10.59 (+1.63%)
GILD   71.05 (-0.95%)
NFLX   505.87 (+1.45%)
DIS   116.71 (+0.31%)
BAC   24.92 (-0.28%)
BA   166.55 (+2.64%)
Log in

NASDAQ:GNPXGenprex Stock Price, Forecast & News

$3.68
-0.03 (-0.81 %)
(As of 08/4/2020 10:15 AM ET)
Add
Compare
Today's Range
$3.60
Now: $3.68
$3.80
50-Day Range
$2.90
MA: $3.21
$4.10
52-Week Range
$0.23
Now: $3.68
$7.03
Volume154,948 shs
Average Volume1.96 million shs
Market Capitalization$142.12 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.9
Genprex, Inc. operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells. Genprex, Inc. was founded in 2009 and is headquartered in Austin, Texas.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.31 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GNPX
CUSIPN/A
Phone512-370-4081

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.15 per share

Profitability

Net Income$-10,650,000.00

Miscellaneous

EmployeesN/A
Market Cap$142.12 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable
$3.68
-0.03 (-0.81 %)
(As of 08/4/2020 10:15 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GNPX News and Ratings via Email

Sign-up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Genprex (NASDAQ:GNPX) Frequently Asked Questions

How has Genprex's stock been impacted by COVID-19 (Coronavirus)?

Genprex's stock was trading at $2.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GNPX stock has increased by 52.3% and is now trading at $3.6846.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Genprex?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genprex in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Genprex
.

When is Genprex's next earnings date?

Genprex is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020.
View our earnings forecast for Genprex
.

How were Genprex's earnings last quarter?

Genprex Inc (NASDAQ:GNPX) announced its quarterly earnings results on Thursday, May, 14th. The company reported ($0.20) EPS for the quarter.
View Genprex's earnings history
.

What price target have analysts set for GNPX?

2 equities research analysts have issued twelve-month price targets for Genprex's stock. Their forecasts range from $5.00 to $5.00. On average, they anticipate Genprex's share price to reach $5.00 in the next year. This suggests a possible upside of 35.7% from the stock's current price.
View analysts' price targets for Genprex
.

Has Genprex been receiving favorable news coverage?

Media stories about GNPX stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Genprex earned a news sentiment score of -1.7 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future.
View the latest news about Genprex
.

Who are some of Genprex's key competitors?

What other stocks do shareholders of Genprex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genprex investors own include Inovio Pharmaceuticals (INO), Opko Health (OPK), Tonix Pharmaceuticals (TNXP), Co-Diagnostics (CODX), Ibio (IBIO), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX), VBI Vaccines (VBIV), FuelCell Energy (FCEL) and vTv Therapeutics (VTVT).

Who are Genprex's key executives?

Genprex's management team includes the following people:
  • Mr. John Rodney Varner, Co-Founder, CEO, Sec. & Chairman (Age 62)
  • Dr. Julien L. Pham M.P.H., M.D., MPH, Pres & COO (Age 42)
  • Mr. Ryan M. Confer, Chief Financial Officer (Age 37)
  • Dr. Jack A. Roth FACS, M.D., Chairman of Scientific & Medical Advisory Board

What is Genprex's stock symbol?

Genprex trades on the NASDAQ under the ticker symbol "GNPX."

Who are Genprex's major shareholders?

Genprex's stock is owned by many different retail and institutional investors. Top institutional shareholders include UBS Group AG (0.03%).
View institutional ownership trends for Genprex
.

Which institutional investors are buying Genprex stock?

GNPX stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG.
View insider buying and selling activity for Genprex
.

How do I buy shares of Genprex?

Shares of GNPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Genprex's stock price today?

One share of GNPX stock can currently be purchased for approximately $3.68.

How big of a company is Genprex?

Genprex has a market capitalization of $142.12 million.

What is Genprex's official website?

The official website for Genprex is www.genprex.com.

How can I contact Genprex?

Genprex's mailing address is 1601 Trinity Street Suite 3.322, AUSTIN TX, 78712. The company can be reached via phone at 512-370-4081 or via email at [email protected]

This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.